Acute aortic dissection during sorafenib-containing therapy.
Serrano
C
C
Suárez
C
C
Andreu
J
J
Carles
J
J
D000368:Aged; D000784:Aortic Dissection / Q000139:chemically induced*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001014:Aortic Aneurysm / Q000139:chemically induced*; D001557:Benzenesulfonates / Q000009:adverse effects*; D000069287:Capecitabine; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D017322:Clinical Trials, Phase II as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007680:Kidney Neoplasms / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib; D000093542:Gemcitabine
D000959:Antihypertensive Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D003841:Deoxycytidine; D009536:Niacinamide; D000069287:Capecitabine; D000077157:Sorafenib; D005472:Fluorouracil; D000093542:Gemcitabine